These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27450534)

  • 1. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.
    Valensi P; Avignon A; Sultan A; Chanu B; Nguyen MT; Cosson E
    Cardiovasc Diabetol; 2016 Jul; 15(1):104. PubMed ID: 27450534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.
    Arca M; Montali A; Valiante S; Campagna F; Pigna G; Paoletti V; Antonini R; Barillà F; Tanzilli G; Vestri A; Gaudio C
    Am J Cardiol; 2007 Nov; 100(10):1511-6. PubMed ID: 17996510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception.
    Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L
    Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Atherogenic Index of Plasma: A Powerful and Reliable Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes.
    Zhou K; Qin Z; Tian J; Cui K; Yan Y; Lyu S
    Angiology; 2021 Nov; 72(10):934-941. PubMed ID: 33949211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of major coronary events by coronary risk profile and silent myocardial ischaemia: prospective follow-up study of primary prevention in 72 diabetic patients.
    Torremocha F; Hadjadj S; Carrié F; Rosenberg T; Herpin D; Maréchaud R
    Diabetes Metab; 2001 Feb; 27(1):49-57. PubMed ID: 11240446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The report of male gender and retinopathy status improves the current consensus guidelines for the screening of myocardial ischemia in asymptomatic type 2 diabetic patients.
    Cosson E; Nguyen MT; Chanu B; Balta S; Takbou K; Valensi P
    Nutr Metab Cardiovasc Dis; 2013 Jun; 23(6):557-65. PubMed ID: 22502874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries.
    Sacks FM; Hermans MP; Fioretto P; Valensi P; Davis T; Horton E; Wanner C; Al-Rubeaan K; Aronson R; Barzon I; Bishop L; Bonora E; Bunnag P; Chuang LM; Deerochanawong C; Goldenberg R; Harshfield B; Hernández C; Herzlinger-Botein S; Itoh H; Jia W; Jiang YD; Kadowaki T; Laranjo N; Leiter L; Miwa T; Odawara M; Ohashi K; Ohno A; Pan C; Pan J; Pedro-Botet J; Reiner Z; Rotella CM; Simo R; Tanaka M; Tedeschi-Reiner E; Twum-Barima D; Zoppini G; Carey VJ
    Circulation; 2014 Mar; 129(9):999-1008. PubMed ID: 24352521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.
    Muhlestein JB; Lappé DL; Lima JA; Rosen BD; May HT; Knight S; Bluemke DA; Towner SR; Le V; Bair TL; Vavere AL; Anderson JL
    JAMA; 2014 Dec; 312(21):2234-43. PubMed ID: 25402757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of dyslipidemia and evaluation of non-HDL cholesterol as a marker of risk factor for cardiovascular disease in type 2 diabetes mellitus.
    Pandeya A; Sharma M; Regmi P; Basukala A; Lamsal M
    Nepal Med Coll J; 2012 Dec; 14(4):278-82. PubMed ID: 24579534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherogenic dyslipidemia in patients with established coronary artery disease.
    Lahoz C; Mostaza JM; Tranche S; Martin-Jadraque R; Mantilla MT; López-Rodriguez I; Monteiro B; Sanchez-Zamorano MA; Taboada M
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):103-8. PubMed ID: 20675108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians.
    Weber M; McNicoll S; Marcil M; Connelly P; Lussier-Cacan S; Davignon J; Latour Y; Genest J
    Can J Cardiol; 1997 Mar; 13(3):253-60. PubMed ID: 9117913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silent myocardial ischemia in patients with diabetes: who to screen.
    Janand-Delenne B; Savin B; Habib G; Bory M; Vague P; Lassmann-Vague V
    Diabetes Care; 1999 Sep; 22(9):1396-400. PubMed ID: 10480499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular risk prediction is improved by adding asymptomatic coronary status to routine risk assessment in type 2 diabetic patients.
    Cosson E; Nguyen MT; Chanu B; Banu I; Chiheb S; Balta C; Takbou K; Valensi P
    Diabetes Care; 2011 Sep; 34(9):2101-7. PubMed ID: 21775753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of high-density lipoprotein cholesterol levels in elderly diabetic individuals with type IIb dyslipidemia: A 2-year survey of cardiovascular events.
    Ina K; Hayashi T; Araki A; Kawashima S; Sone H; Watanabe H; Ohrui T; Yokote K; Takemoto M; Kubota K; Noda M; Noto H; Ding QF; Zhang J; Yu ZY; Yoon BK; Nomura H; Kuzuya M;
    Geriatr Gerontol Int; 2014 Oct; 14(4):806-10. PubMed ID: 24215618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM).
    Raj R; Bhatti JS; Badada SK; Ramteke PW
    Diabetes Metab Res Rev; 2015 Oct; 31(7):663-71. PubMed ID: 25470794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent association between triglycerides and coronary artery disease in Taiwanese type 2 diabetic patients.
    Tseng CH; Tseng CP; Chong CK; Cheng JC; Tai TY
    Int J Cardiol; 2006 Jul; 111(1):80-5. PubMed ID: 16213608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic dyslipidemia in patients with transient ischemic attack.
    Sirimarco G; Deplanque D; Lavallée PC; Labreuche J; Meseguer E; Cabrejo L; Guidoux C; Olivot JM; Abboud H; Lapergue B; Klein IF; Mazighi M; Touboul PJ; Bruckert E; Amarenco P
    Stroke; 2011 Aug; 42(8):2131-7. PubMed ID: 21737806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.